Business
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven
About this update from Palvella Therapeutics, Inc.
[{"type":"text","content":"Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the crystallization, stability, and dermal penetration challenges posed by rapamycin Poster #76929 highlights a qualitative patient and caregiver interview study evaluating the burden of living with porokeratosis, a serious, rare genetic skin disease characterized by numerous pre-cancerous, pruritic lesions and substantial functional and psychosocial burden WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., (“Palvella” or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced two poster presentations at the 2026 American Academy of Dermatology Annual Meeting to be held March 27-31 in Denver, Colorado. “The data presented in these posters highlight the innovative capabilities of the QTORIN™ platform as well as Palvella’s unwavering commitment to incorporating the voice of the patient in our development programs,” said Dr. Jeff Martini, Chief Scientific Officer of Palvella Therapeutics. “With patients in mind, we developed QTORIN™ rapamycin as a single-phase anhydrous gel designed to prevent crystallization and degradation of rapamycin with the goal of ensuring rapamycin bioavailability in the dermis, the site of disease pathology for many mTOR-driven skin diseases. Furthermore, our porokeratosis qualitative burden-of-living study, incorporating both patient and caregiver perspectives, confirms that porokeratosis is a life-altering condition with no FDA-approved therapies, imposing substantial physical, psychosocial, and cancer-related burdens that affect daily life in profound ways.” The details of the poster presentations are as follows: Poster #76954: QTORIN™ Rapamycin: Advancing Topical Formulation Science for Rare Dermatologic Diseases QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) was developed over many years by Palvella and an international team of leading topical formulation scientists. This work addressed rapamycin’s crystallization, stability...